



RECEIVED PCT/PTO 06 FEB 2003

PCT

PTO/SB/64 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

11

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED
UNINTENTIONALLY UNDER 37 CFR 1.137(b)**

Docket Number (Optional)

First named inventor: Stefan Masure, et. al.

Application No.: 10/019,337

Int.No. PCT/EP00/04918

Filed: I.A. March 26, 2000

Art Unit:

Examiner:

Title: NEUROTROPHIC FACTOR RECEPTOR

Attention: Office of Petitions
Assistant Commissioner for Patents
Box DAC
Washington, D.C. 20231NOTE: If information or assistance is needed in completing this form, please contact Petitions
Information at (703) 305-9282.The above-identified application became abandoned for failure to file a timely and proper reply to a
notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the
expiration date of the period set for reply in the Office notice or action plus an extensions of time
actually obtained.**APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION**

NOTE: A grantable petition requires the following items:

- (1) Petition fee;
- (2) Reply and/or issue fee;
- (3) Terminal disclaimer with disclaimer fee --required for all utility and plant applications
filed before June 8, 1995; and for all design applications; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee☐ Small entity-fee \$_____ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.☒ Other than small entity - fee \$1280 (37 CFR 1.17(m))**2. Reply and/or fee****A. The reply and/or fee to the above-noted Office action in**the form of responses to notice of missing (identify type of reply):

- ☐ has been filed previously on parts & notice of defective response
☒ is enclosed herewith. dated 3/6/02 & 6/28/02, respectively

B. The issue fee of \$_____

- ☐ has been paid previously on _____
☐ is enclosed herewith.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on
the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC
20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



3. Terminal disclaimer with disclaimer fee

- ☐ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.
- ☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ _____ for a small entity or \$ _____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE. The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D))].

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

January 31, 2003
Date

Myra McCormack
Signature

Telephone
Number: () 732-524-6932

Myra H. McCormack, Reg. # 36,602
Typed or printed name

Johnson & Johnson/One J&J Plaza
Address

Enclosures: ☒ Fee Payment

New Brunswick, NJ 08933

☒ Reply

☐ Terminal Disclaimer Form

☐ Additional sheets containing statements establishing unintentional delay

☐ Other: _____

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box DAC, Washington, D.C. 20231.

☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 308-6916.

January 31, 2003
Date

Myra McCormack
Signature

Myra H. McCormack
Typ or printed name of person signing certificate



DOCKET NO. JAB-1512

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MASURE, et al

Serial No.: 10/019,337

Art Unit: UNKNOWN

I. A. Filed: March 26, 2000

Examiner: UNKNOWN

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, Washington, DC 20231 on

January 31, 2003

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)


(Signature)

January 31, 2003

(Date of Signature)

Commissioner For Patents
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Notification of Missing Requirements under 35 USC 371 as dated 6 March 2002. An Amendment responding to the aforesaid Notification is being filed concurrently herewith.

Please charge Deposit Account No. 10-0750/JAB-1512/MHM in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,




Myra H. McCormack

Reg. No. 36,602

Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATE: January 31, 2003



DOCKET NO. JAB-1512

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MASURE, et al

Serial No.: 10/019,337

Art Unit: UNKNOWN

I. A. Filed: March 26, 2000

Examiner: UNKNOWN

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, Washington, DC 20231 on

January 31, 2003

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)

Myra H. McCormack
(Signature)

January 31, 2003

(Date of Signature)

Commissioner For Patents
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Notification of Missing Requirements under 35 USC 371 as dated 6 March 2002. An Amendment responding to the aforesaid Notification is being filed concurrently herewith.

Please charge Deposit Account No. 10-0750/JAB-1512/MHM in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,

Myra H. McCormack

Myra H. McCormack

Reg. No. 36,602

Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATE: January 31, 2003



DOCKET NO. JAB-1512

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MASURE, et al

Serial No.: 10/019,337

Art Unit: UNKNOWN

I. A. Filed: March 26, 2000

Examiner: UNKNOWN

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on

January 31, 2003

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)

Myra H. McCormack
(Signature)

January 31, 2003

(Date of Signature)

Commissioner For Patents
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Notification of Missing Requirements under 35 USC 371 as dated 6 March 2002. An Amendment responding to the aforesaid Notification is being filed concurrently herewith.

Please charge Deposit Account No. 10-0750/JAB-1512/MHM in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,

Myra H. McCormack

Myra H. McCormack

Reg. No. 36,602

Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATE: January 31, 2003



Docket No. JAB1512

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Masure, et. al.

Serial No. : 10/019,337

Art Unit: unknown

I.A. Filed : March 26, 2000

Examiner: unknown

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

January 31, 2003

(Date)

Myra H. McCormack

Name of applicant, assignee, or Registered Representative

Myra H. McCormack
(Signature)

January 31, 2003

(Date of Signature)

Hon. Commissioner for Patents
Washington, D.C. 20231

Response to the Notice to Comply with Sequence Requirements

Dear Sir:

In response to the Notice to Comply with Requirements for
Patent Applications Containing Nucleotide Sequence and/or Amino
Acid Sequence disclosures, Applicants submit the requested
sequence together with a Petition for Revival of an Application
for Patent Abandoned Unintentionally.

IN THE SPECIFICATION:

Kindly delete the existing sequence listing and in the substitute sequence listing provided herewith.

REMARKS

A substitute sequence listing along with a Computer Readable Form of the Sequence Listing is provided herewith. The undersigned hereby states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR 1.821 are identical. No new matter has been added by this amendment. A favorable examination of the Application is respectfully requested.

Should the Examiner have any questions he is invited to contact the under signed at the telephone number provided below.

Respectfully submitted,



Myra H. McCormack, Ph.D.
Attorney for Applicants
Reg. No. 36,602

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
Dated: January 31, 2003



15 JAN 2003

UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

PATENT INFORMATION
SERVICES

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

JAN 21 2003

49

Myra H. McCormack
Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003

TO FILE REFER TO

In re Application of	:	
MASURE, et al.	:	
U.S. Application No.: 10/019,337	:	COMMUNICATION AND
PCT No.: PCT/EP00/04918	:	
Int. Filing Date: 26 March 2000	:	NOTIFICATION OF
Priority Date: 29 June 1999	:	
Attorney Docket No.: JAB-1512	:	ABANDONMENT
For: NEUROTROPHIC FACTOR RECEPTOR	:	

This communication is in response to the "Petition For Extension of Time" and "Response to Notification of Defective Response" filed 30 December 2002 in the United States Patent and Trademark Office (USPTO).

BACKGROUND

On 26 March 2000, applicant filed international application PCT/EP00/04918, which claimed priority of an earlier application filed 29 June 1999. A Demand for international preliminary examination electing the United States was filed prior to the expiration of nineteen months from the priority date. Accordingly, the thirty-month period for paying the basic national fee in the United States expired at midnight on 29 December 2001.

On 19 December 2001, applicant filed a transmittal letter for entry into the national stage in the United States, which was accompanied by, inter alia: payment of the basic national fee; an executed declaration; an Information Disclosure Statement and a First Preliminary Amendment.

On 06 March 2002, applicant was mailed a "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371" (Form PCT/DO/EO/905) informing applicant of the need to provide a nucleotide and/or amino acid sequence disclosure in compliance with 37 CFR 1.821-1.825. Applicant was afforded two months to file the response.

On 17 April 2002, applicant responded with an amendment to the specification; applicant did not include a computer readable diskette version of the sequence listing.

On 28 June 2002, applicant was mailed a "NOTIFICATION OF DEFECTIVE RESPONSE" (Form PCT/DO/EO/916) informing applicant that the sequence listing filed 17 April 2002 did not comply 37 CFR 1.821-1.825 and thus was not a proper response to the Form PCT/DO/EO/905 mailed 06 March 2002. Applicant was afforded one month from the mailing of the Form PCT/DO/EO/916 or within the time remaining in the response set forth in the Form PCT/DO/EO/905, whichever was longer.

On 30 December 2002, applicant filed the present petition and response considered herein.

DISCUSSION

The above-identified application was **ABANDONED** on 06 October 2002 for failure to respond to the Form PCT/DO/EO/916 within the time period prescribed therein. Applicant is seeking a five month extension of time from the mail date of the Form PCT/DO/EO/916. However, the only extendable time available was to be calculated from the mail date of the Form PCT/DO/EO/905 mailed 06 March 2002. Thus, the response filed 30 December 2002 is untimely.

RECOMMENDATION

Applicants may wish to consider filing a petition to the Commissioner under 37 CFR 1.137(a) or (b) requesting that the application be revived. Any petition filed under 37 CFR 1.137(a) and/or a petition under 37 CFR 1.137(b) requesting that the application be revived must meet the criteria indicated in the recent revision of 37 CFR 1.137. See 62 Fed. Reg. 53131 (October 10, 1997); 1203 Off. Gaz. Pat. Office 63 (October 21, 1997) (Effective Date: 01 December 1997).


This recommendation to file a petition under 37 CFR 1.137(a) or (b) should not be construed as an indication as to whether or not any such petition(s) will be favorably considered.


CONCLUSION

The application is **ABANDONED** as to the United States of America.

This application is being forwarded to the United States Designated/Elected Office (DO/EO/US) for mailing of a "Notification of Abandonment" (Form PCT/DO/EO/909).

Any further correspondence with respect to this matter should be addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231, with the contents of the letter marked to the attention to the PCT Legal Office


Richard Cole
Legal Examiner
PCT Legal Office


Derek A. Putonen
Attorney Advisor
PCT Legal Office
Tel: (703) 305-0130
Fax: (703) 308-6459



SEQUENCE LISTING

<110> Masure, Stefan
Cik, Miroslav
Hoefnagel, Evert

<120> Neurotrophic Factor Receptor

<130> 53202/001

<140> PCT/EP00/04918

<141> 2000-05-26

<150> GB 9915200.1

<151> 1999-05-29

<160> 31

<170> PatentIn Ver. 2.0

<210> 1

<211> 792

<212> DNA

<213> Mus musculus

<220>

<221> misc_feature

<222> (583)..(583)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (611)..(611)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (637)..(637)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (664)..(664)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (684)..(684)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (689)..(689)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (728)..(728)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (734)..(734)

<223> n = any amino acid

<220>

<221> misc_feature

<222> (742)..(742)

<223> n = any amino acid

<400> 1

```
gtgcgccgag cgccggcgcc agactttcgc gcccgccctgc gcgttctccg gcccggggtt 60
ggtgccgccc tcttgccctgg agcccctgga gcgctgcgag cgcagccgcc tgtgccgggtg 120
cgtgcgtgcg gggcgggctg ggccgctcac ccgcgtccgg gcgcgcgcag gccccgtctc 180
cttgcccttc aggcctcatg cgtccccgcg cccggctccc gcgaccgctg cccggaggag 240
gggggcccgc gttgtctgcg cgtctacgca ggcctcatgg gcaccgtggt caccaccaac 300
tacctggaca acgtgagcgc gcgcgttgcg ccctggtgcg gctgtgcggc cagtggaaac 360
cggcgcgaaag aatgcgaagc cttccgcaag ctctttacaa ggaacccctg cttgggtgag 420
ggggcctgga ggtcccgggg aaccacggat gtctgtggcc caatccaagc tgctggccc 480
gtgggtctta ttacgtcgc atcatgtttg gtgtgggcca tggacaatgt gcacatgcc 540
tggtacgtgg gtggaagtca agcgttaaaa cgtgtccaat ggnctggaag ttggccttcc 600
ttttgacact natgggggtg gcctttcttc atggtgngcc caacttacct ttggttggtc 660
ttgncctctg gtgggaatgg cttnaattnc agaattttgg gggctctgtt tgaagcctgg 720
cttttgcnct taanaacttg anaagttaaa ctcttattaa toccaatggg gttcacctgt 780
aaagggagag gg 792
```

<210> 2

<211> 497

<212> DNA

<213> Mus musculus

<400> 2

```
gtggaaccgg cgcaagaat gcgaaccttc cgcaagctct ttacaaggaa cccctgcttg 60
gatggtgcc tacaagcctt tgacagcttg cagccatcag ttctgcagga ccagactgct 120
gggtgctgtt tcccgcgggc aaggcacgag tggcctgaga agagctggag gcagaaacag 180
tccttgtttt gtcctaacgc ccaaggtgtc ctggctgtat gcactcactg ccctggctct 240
ccaggccctg ctctgattag gaacatgaac cgtggacgac acagctgact gccatgtctc 300
ccgatgactg ctactgagc tgaaactccc ttgccctcag gtctgctgcc ctttgaggc 360
ctggacccct gtgtggctgt cctctggatt gggggctgga ggctagggc tgactgaaaa 420
gcctgtgttc ccgtcagtag gcattctgtc cattttcttc cccatcctag agctgagcac 480
ccatagatga ggcctca 497
```

<210> 3

<211> 901

<212> DNA

<213> Rattus rattus

<400>. 3

```
ggcaccgtgg tcacccccaa ctacctggac aacgtgagcg cgcgcgttgc gccctgggtgc 60
ggctgtgagg ccagcggaaa cgggcgcgaa gagtgcgaag ccttccgcaa gctttttaca 120
aggaaccctt gcttggatgg tgccatacaa gcctttgaca gctcgcgaacc atcagttctg 180
caggaccagt ggaaccctta ccagaatgct ggggtgctgtt tcctgtgggt gtcctcgatg 240
tccatactca ctgccctggc tctccaggcc ctgctctaata taggaagggtg aacctatggac 300
aacacagctg actgccatgt ctctggatta tgctcactga actgaaactc ccttgccctc 360
aggtctgctg tcctttgcag ttctggaccc ctgcatggct gtctcctgga ctgggagctg 420
gaggctaggg cccgactggt aggttccctt gttagtaggc atctcgctg ttttcttcac 480
catccttgag atgatggtag atgatattta gcacctgtag acagggcctc attgggcccc 540
ttgggcttac agagcagaac agagactagc ctctgctct tagaattggg tagtgttctt 600
ttccaagaag acatggcact aaggcgatca tatgaacaga ctgacagact gcagtctaaa 660
taccatgcc ccagggccag cgctgacctt gcttgtcacc tatgacatgg cgctgtgtag 720
ggattaaaga gagagattca ggtccctcct gctggacatc ccactggcct cccagactct 780
cccagcacct gcagtggcac agcagctcaa taaacccatg tgcactggaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaagaaaa aaaaaaaaaa 900
a                                                                                      901
```

<210> 4

<211> 872

<212> DNA

<213> Rattus rattus

<400> 4

```
gtatggggag aggatgtgga gttggcagtt tctcatcggt cccttctgta tttacccttc 60
tcaggcaggc caaggtggag gcctgagtgg cctgagaaga gatggaggca gaaacgggtcc 120
ccgttttgtc ccaaggtgtc ctcgatgtcc atactcactg ccctggctct ccaggccctg 180
ctctaattag gaaggtgaac catggacaac acagctgact gccatgtctc tggattatgc 240
tcaactgaact gaaactccct tgccctcagg tctgctgtcc tttgcagttc tggaccctg 300
catggctgtc tcctggactg ggagctggag gctagggccc gactgttagg ttccctgtt 360
agtaggcac tcgcctgttt tcttcaccat ccttgagatg atggtagatg atatttagca 420
cctgtagaca gggcctcatt gggcccttg ggcttacaga gcagaacaga gactagcctc 480
ctgctcttag aattgggtag tgttcttttc caagaagaca tggcactaag gcgatcatat 540
gaacagactg acagactgca gtctaaatac ccatgccccca gggccagcgc tgaccttgct 600
tgtcacctat gacatggcgc tgtgtagggg ttaaagagag agattcaggt ccctcctgct 660
ggacatccca ctggcctccc agactctccc agcacctgca gtggcacagc agctcaataa 720
accatgtgc actggaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaagaaa aaaaaaaaaa aa                                                                                      872
```

<210> 5

<211> 2522

<212> DNA

<213> Rattus rattus

<400> 5

```
ctggtaagct ttaaggcaga ggagacctaa gagctgagac atgctatggt gagtggagcg 60
tatttacggg tgctgaatga gaggccaggc caggcagttt tatggagtct tggatgccag 120
agaggtaagg aggtgggaaa ggaagtacta taaacctgaa tttggtgact tggctggatt 180
tgcatatgtc cagtgccaaag ttcagacata gctgccgggt ttactgatgc tactctcca 240
aggtcaggca ttctattttc ccctgaatgg cttttcatct gtgacttate tacatcttca 300
ctgaaactac tggtaaactg ccaggctctgt ctccaggcga agtcctatgg tctgccatta 360
agcctcagtg tcctgtcagg tgaagctggg gaggatggaa ggggtccagt agacgctctg 420
tgatgcatgt gccagttctg gagatgggtg tggaggctga acctgagctt ctggggaacc 480
tccgagtact gcctccattc acgacctggg tggatatccc taggacctgc ccatgccgc 540
ttcctcagga aaacagggtc acgcctatgg gccacactct ctcccttggt gtttgggtat 600
ctgccccag ccccgccaa attccgggggt gtggaatgtg gagaaccaag cacagagggc 660
```

tgcagcctgc	cctccccctca	ccaggggtcag	cgagctccac	tgaggggaat	cgctgcgtgg	720
aagcagccga	ggcgtgcaca	gcagacgagc	agtgccagca	gctgcgctcc	gagtacgtgg	780
cgcaatgcct	gggcccggcg	ggctggcggg	gacccgggag	ctgcgtgcgc	tcccgtgcc	840
gccgtgccct	gcgcgccttc	ttcgcccgcg	ggcctccggc	gtcacgcac	gcgtgtctct	900
tctgcggatg	cgaaggcccc	gcgtgcgcgg	agcgccggcg	ccagacattc	gcgcccgcct	960
gcgcgtttct	cggccccccag	ctggcgccac	cttcctgcct	gaagcccttg	gaccgtgcg	1020
agcgaagccg	ccggtgccgg	tgcggtgcgg	gcgggctggg	ccgctcaccg	gcgtccgggc	1080
gcgcgcaggc	cccgctctctt	tgccctccag	gcctcatgcg	ctcccgcgcc	cggctcccgc	1140
gacggctgtc	eggaggaggg	gggcccgcgg	tgtctgcgcg	cctacgcagg	ccttgtaggt	1200
acgctggggc	gcctctggcg	ggcggggcgg	cggaggcaga	ttccgggggc	ccgtcacagg	1260
tccctgggggt	ccctgcaggc	accgtgggtca	cccccaacta	cctggacaac	gtgagcgcg	1320
gcgttgccgc	ctgggtgcggc	tgtgaggcca	gcggaaaccg	gcgcgaagag	tgcaagcct	1380
tccgcaagct	ttttacaagg	aacccctgct	tggggtgagg	ggctggagag	cccgggcaac	1440
caaggacgtc	tatggcccag	tctaggctgc	ctggcctgtg	gggaccctta	aaatgttttc	1500
gtcgtgtcgt	atttggtgtg	ggtgatggac	agtgtgcacg	tgccatgggtg	catgggtgga	1560
agtcagagga	caacttgtca	gtctctttct	accacgtggg	tccccgggat	agcactgggc	1620
tcatcagttt	tgggtggcaag	tgcccttgcc	tgtgagcca	tcttgctggc	tgatgtgagc	1680
acatttttga	tggaaagaaa	ctgagggttc	cagagaccag	atagccgatc	actagagaat	1740
tgcagagatg	tcaagaatct	cttagggcta	gaaaggatga	gttaaaacat	gtccaatgac	1800
ctggagtttg	ccaaggctcc	ctttggcact	actgagggtct	tttctcccat	gtgttcccaa	1860
tttaacgctg	ctgttcttgc	ctcgggatga	aatagcgttg	ttccagattt	ctggggggccc	1920
ggtttgaagc	ctgtctctgc	cacttcgtag	ccgagagtta	aactcttatt	aatcctaatt	1980
gtgttcacct	gtaagggcgg	ggtgtgcact	tgtcaacctc	actcttagca	cagtgcacct	2040
ccatctcagg	ccgtgccttg	cagattccag	gggggtgtct	atcttctctc	aagggtgagg	2100
agctgtttct	agggtttctt	ggccaaacct	tctctggatc	tctccactcc	atagatgggtg	2160
ccatacaagc	ctttgacagc	tgcgaacct	cagttctgca	ggaccagtgg	aacccctacc	2220
agaatgctgg	gtgctgtttc	ctgtgggtag	gtatggggag	aggatgtgga	gttggcagtt	2280
tctcatcggt	cccttctgta	tttacccttc	tcaggcaggc	caagggtggag	gcctgagttg	2340
cctgagaaga	gatggaggca	gaaacgggtcc	ccgttttgtc	ccaagggtgc	ctcgatgtcc	2400
atactcactg	ccctggctct	ccaggccctg	ctctaattag	gaagggtgaac	catggacaac	2460
acagctgact	gccatgtctc	tggattatgc	tcactgaact	gaaactccct	tgccctcagg	2520
tc						2522

<210> 6

<211> 953

<212> DNA

<213> Rattus rattus

<400> 6

ctggtaagct	ttaaggcaga	ggagacctaa	gagctgagac	atgctatgtt	gagtggagcg	60
tattttacgg	tgctgaatga	gaggccaggc	caggcagttt	tatggagtct	tggatgccag	120
agagggctag	cgagctccac	tgaggggaat	cgctgcgtgg	aagcagccga	ggcgtgcaca	180
gcagacgagc	agtgccagca	gctgcgctcc	gagtacgtgg	cgcaatgcct	gggcccggcg	240
ggctggcggg	gacccgggag	ctgcgtgcgc	tcccgtgcc	gccgtgccct	gcgcgccttc	300
ttcgcccgcg	ggcctccggc	gtcacgcac	gcgtgtctct	tctgcggatg	cgaaggcccc	360
gcgtgcgcgg	agcgccggcg	ccagacattc	gcgcccgcct	gcgcgttctc	cggccccccag	420
ctggcgccac	cttcctgcct	gaagcccttg	gaccgtgcg	agcgaagccg	ccggtgccgg	480
ccccgtctct	ttgccttcca	ggcctcatgc	gctcccgcgc	ccggctcccg	cgacggctgt	540
ccggaggagg	ggggcccgcg	gtgtctgcgc	gcctacgcag	gccttgtagg	caccgtggtc	600
acccccaaact	acctggacaa	cgtgagcgcg	cgcgttgccg	cctgggtgcgg	ctgtgaggcc	660
agcggaaacc	ggcgcgaaga	gtgcgaagcc	ttccgcgaagc	tttttacaag	gaacccctgc	720
ttggatgggtg	ccatacaagc	ctttgacagc	tgcgaacct	cagttctgca	ggaccagtgg	780
aacccctacc	agaatgctgg	gtgctgtttc	ctgtgggtgt	cctcgatgtc	catactcact	840
gccctggctc	tccaggccct	gctctaatta	ggaagggtgaa	ccatggacaa	cacagctgac	900
tgccatgtct	ctggattatg	ctcactgaac	tgaactccc	ttgccctcag	gtc	953

<210> 7

<211> 1008
 <212> DNA
 <213> Rattus rattus

<400> 7

```

ctggtaagct ttaaggcaga ggagacctaa gagctgagac atgctatgtt gaggaggagcg 60
tatttacggg tgctgaatga gaggccaggc caggcagttt tatggagtct tggatgccag 120
agaggggtcag cgagctccac tgaggggaat cgctgcgtgg aagcagccga ggcgtgcaca 180
gcagacgagc agtgccagca gctgcgctcc gactacgtgg cgcaatgcct gggccggggcg 240
ggctggcggg gaccggggag ctgcgtgcgc tcccgtgcc gccgtgccct gcgccgcttc 300
ttcgcccgcg ggccctccgc gctcacgcac gcgctgctct tctgcggatg cgaaggcccc 360
gcgtgcgcgc agcgccggcg ccagacattc gcgccgcct gcgcgttctc cggccccag 420
ctggcgccac ctctctgcct gaagcccttg gaccgctgcg agcgaagccg ccggtgccgg 480
ccccgtctct ttgccttcca ggccctcatgc gctcccgcgc ccggctcccg cgacggctgt 540
ccggaggagg ggggcccgcg gtgtctgcgc gcctacgcag gccttgtagg caccgtggtc 600
acccccaact acctggacaa cgtgagcgcg cgcgttgcgc cctggtgcgg ctgtgaggcc 660
agcggaacc ggcgcgaaga gtgcgaagcc ttccgcaagc tttttacaag gaaccctgc 720
ttggatggtg ccatacaagc ctttgacagc tcgcaaccat cagttctgca ggaccagtgg 780
aaccctacc agaatgctgg gcaggccaag gtggaggcct gaggggcctg agaagagatg 840
gaggcagaaa cgggtcccgt tttgtccaa ggtgtcctcg atgtccatac tactgcccct 900
ggctctccag gccctgctct aattaggaag gtgaaccatg gacaacacag ctgactgcca 960
tgtctctgga ttatgctcac tgaactgaaa ctcccttgcc ctcaggtc 1008
  
```

<210> 8
 <211> 273
 <212> PRT
 <213> Rattus rattus

<400> 8

```

Met Leu Ser Gly Ala Tyr Leu Arg Val Leu Asn Glu Arg Pro Gly Gln
  1             5             10             15

Ala Val Leu Trp Ser Leu Gly Cys Gln Arg Gly Ser Ala Ser Ser Thr
      20             25             30

Glu Gly Asn Arg Cys Val Glu Ala Ala Glu Ala Cys Thr Ala Asp Glu
      35             40             45

Gln Cys Gln Gln Leu Arg Ser Glu Tyr Val Ala Gln Cys Leu Gly Arg
      50             55             60

Ala Gly Trp Arg Gly Pro Gly Ser Cys Val Arg Ser Arg Cys Arg Arg
      65             70             75             80

Ala Leu Arg Arg Phe Phe Ala Arg Gly Pro Pro Ala Leu Thr His Ala
      85             90             95

Leu Leu Phe Cys Gly Cys Glu Gly Pro Ala Cys Ala Glu Arg Arg Arg
      100            105            110

Gln Thr Phe Ala Pro Ala Cys Ala Phe Ser Gly Pro Gln Leu Ala Pro
      115            120            125

Pro Ser Cys Leu Lys Pro Leu Asp Arg Cys Glu Arg Ser Arg Arg Cys
      130            135            140

Arg Pro Arg Leu Phe Ala Phe Gln Ala Ser Cys Ala Pro Ala Pro Gly
  
```


Pro Ser Cys Leu Lys Pro Leu Asp Arg Cys Glu Arg Ser Arg Arg Cys
 130 135 140
 Arg Pro Arg Leu Phe Ala Phe Gln Ala Ser Cys Ala Pro Ala Pro Gly
 145 150 155 160
 Ser Arg Asp Gly Cys Pro Glu Glu Gly Gly Pro Arg Cys Leu Arg Ala
 165 170 175
 Tyr Ala Gly Leu Val Gly Thr Val Val Thr Pro Asn Tyr Leu Asp Asn
 180 185 190
 Val Ser Ala Arg Val Ala Pro Trp Cys Gly Cys Glu Ala Ser Gly Asn
 195 200 205
 Arg Arg Glu Glu Cys Glu Ala Phe Arg Lys Leu Phe Thr Arg Asn Pro
 210 215 220
 Cys Leu Asp Gly Ala Ile Gln Ala Phe Asp Ser Ser Gln Pro Ser Val
 225 230 235 240
 Leu Gln Asp Gln Trp Asn Pro Tyr Gln Asn Ala Gly Gln Ala Lys Val
 245 250 255

Glu Ala

<210> 10
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCT primer

<400> 10
 cgcgttgtct ggcgtctac g

21

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<400> 11
 cggcgcgaag aatgcgaagc

20

<210> 12
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 12
caccacgta ccatggcatg tgc

23

<210> 13
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 13
gtggtcaccc ccaactacct gg

22

<210> 14
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 14
gccttccgca agctttttac aagg

24

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 15
gctcttctgc ggatgcgaag gc

22

<210> 16
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 16
agtgccggg ttactgatg ctac

24

<210> 17
<211> 24
<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<400> 17
 gatgctactc tcccaaggtc aggc 24

<210> 18
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<400> 18
 ctggtaagct ttaaggcaga ggagacc 27

<210> 19
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<400> 19
 catggcagtc agctgtgttg tcc 23

<210> 20
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<400> 20
 cagctgtggt gtccatgggt cacc 24

<210> 21
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<400> 21
 tggttgcgag ctgtcaaagg cttgtatggc 30

<210> -22
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PCR primer

 <400> 22
 ggggttcctt gtaaaaagct tgcggaaggc 30

 <210> 23
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PCR primer

 <400> 23
 ggtccaaggg cttcaggcag gaagg 25

 <210> 24
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PCR primer

 <400> 24
 gccttcgcat ccgcagaaga gc 22

 <210> 25
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PCR primer

 <400> 25
 ccaggtagtt gggggtgacc acg 23

 <210> 26
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PCR primer

 <400> 26

cccaggcatt gcgccacgta

20

<210> 27

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 27

cattgcgccca cgtactcgga gc

22

<210> 28

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 28

gacctgaggg caaggagatt tca

23

<210> 29

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 29

gcaagggagtt ttcagttcag tgagc

25

<210> 30

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 30

ccatcctaatac gactcact atagggc

27

<210> 31

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223>•Description of Artificial Sequence:PCR primer

<400> 31

actcactata gggctcgagc ggc

23